IFF Trims Portfolio, Sells Food Ingredients Unit to CVC for $4.3 B

International Flavors & Fragrances (IFF) announced that it will sell its Food Ingredients division to funds advised by CVC Capital Partners. The transaction values the business at about $4.3 billion, representing an enterprise value‑to‑EBITDA multiple of roughly 10x based on the segment’s 2025 earnings of $430 million on $3.1 billion in revenue. IFF will retain a roughly 10% equity interest—estimated at $200 million—and a board seat, preserving upside participation while handing day‑to‑day control to CVC.

The divestiture is the latest step in IFF’s multi‑year portfolio simplification program. Since 2021 the company has sold 13 non‑core assets, generating close to $10 billion in cash that has been used to strengthen the balance sheet and fund growth in its core businesses: Taste, Scent, and Health & Biosciences. By shedding a lower‑margin, capital‑intensive segment, IFF expects to improve free cash flow conversion, reduce overhead, and increase financial flexibility for strategic investments such as research‑and‑development and biotechnology integration.

For investors, the deal carries both short‑term earnings pressure and longer‑term upside. IFF projects that adjusted EPS will be diluted in the first twelve months after closing as integration costs and the loss of Food Ingredients’ contribution are absorbed. However, management believes the net cash proceeds—approximately $3.8 billion after taxes and carve‑out expenses—will be deployed to accelerate growth in its remaining high‑margin businesses and to return capital to shareholders. The company reiterated its 2026 guidance: revenue of $10.5‑$10.8 billion and adjusted EBITDA of $2.05‑$2.15 billion, implying comparable‑currency sales growth of 1%‑4% and EBITDA expansion of 3%‑8%.

From a market perspective, the Food Ingredients segment operates in an attractive, resilient space driven by rising global food consumption and demand for clean‑label, plant‑based solutions. CVC’s endorsement underscores the sector’s long‑term growth potential, but the sale also signals that IFF views the business as non‑core relative to its strategic thrust toward biosciences and natural ingredients. Investors should note that retaining a minority stake keeps IFF linked to any upside from this growing market, while allowing the private equity owner to pursue scale‑oriented initiatives such as broader commercial expansion or additional acquisitions.

The transaction is expected to close by the end of Q2 2027, subject to customary regulatory approvals. In the interim, IFF will focus on executing cost‑saving measures tied to “stranded overhead” from the carve‑out and on deploying cash toward high‑return projects. The company’s share price currently sits at $78.03, roughly 12% below its 52‑week high but up over 15% year‑to‑date, reflecting investor optimism about its transformation roadmap. Consensus price targets suggest an upside of about 13%, indicating that the market is pricing in successful execution of the portfolio shift.

Overall, IFF’s decision to sell its Food Ingredients business aligns with a broader industry trend where specialty chemical firms are shedding lower‑margin lines to concentrate on innovation and higher‑growth niches. The cash infusion should bolster liquidity, support dividend or buyback flexibility, and enable the company to double down on biosciences—a segment that could command premium valuations as consumer preferences tilt toward health‑focused ingredients. Investors will need to monitor integration progress, the impact of overhead reductions on margins, and whether the retained stake in Food Ingredients delivers meaningful returns over the medium term.